MARIA TERESA
BERNAL DEL CASTILLO
Profesora Asociada en CC. Salud - LOSU
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (28)
2024
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
-
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670
-
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Haematologica, Vol. 109, Núm. 1, pp. 115-128
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety
Trials, Vol. 24, Núm. 1
-
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
HemaSphere
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
2022
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
Therapeutic Advances in Hematology, Vol. 13
-
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295
2021
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717
-
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2018
-
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55–65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
Leukemia Research, Vol. 68, pp. 79-84
-
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 1, pp. 146-154
2017
-
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid
Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075